title: [Construction and immunological study of recombinant hBD-2/PSMA chimeric protein eukaryotic expressive plasmid].
abstract: The recombinant PSMA DNA vaccine for active immunotherapy of prostate cancer was investigated. Two DNA vaccine recombinant plasmids, pcDNA3.1/PSMA and pcDNA3.1/hBD-2-PSMA, were constructed by inserting the hBD-2 gene and PSMA gene into an eukarytoic expression vector pcDNA3.1. Expression of the two recombinants was detected in transfected COS-7 cells and inoculated mouse muscular cells by RT-PCR and immunohistochemical method. When immunized with pcDNA3.1/PSMA and pcDNA3.1/hBD-2-PSMA, the immunized BALB/c mice acquired specific antibody and T cell response to PSMA. The quantity of the spleen lymphocytes and their CTL activity against PSMA gene transfected-BALB/3T3 cells significantly increased in the immunized mice, and the CTL activity of lymphocytes from pcDNA3.1/hBD-2-PSMA immunized mice was significantly higher than that of pcDNA3.1/PSMA immunized mice. This result suggests that pcDNA3.1/hBD-2-PSMA would probably be developed as a DNA vaccine for the immunotherapy of prostate cancer.
authors.affiliation: Research Institute of Infection and Immunity, West China Medical Center of Sichuan University, Chengdu 610041, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.forename: Yun
authors.initials: Y
authors.lastname: Feng
authors.forename: Qi
authors.initials: Q
authors.lastname: Wu
authors.forename: Ning
authors.initials: N
authors.lastname: Huang
authors.forename: Boyao
authors.initials: B
authors.lastname: Wang
mesh_terms: D016475:3T3 Cells; D000818:Animals; D005057:Eukaryotic Cells / Q000378:metabolism; D005822:Genetic Vectors; D006801:Humans; D016233:Immunotherapy, Active; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids / Q000276:immunology; D017430:Prostate-Specific Antigen / Q000235:genetics / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014162:Transfection; D014407:Tumor Cells, Cultured; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*; D023083:beta-Defensins / Q000235:genetics / Q000276:immunology*
chemical_list: D011993:Recombinant Fusion Proteins; D019444:Vaccines, DNA; D023083:beta-Defensins; D017430:Prostate-Specific Antigen